Gufic Biosciences Limited · NSE:GUFICBIO
Gufic Biosciences — Investor Presentation (June 2021)
24 slides from Gufic Biosciences's investor presentation, Jun 8, 2021
Slide 1: Delivering Care & Cure
Delivering Care & Cure Gu ic moving in the right direction
Slide 2: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties including impact of Covid-19 and other factors that
Slide 3: FY 2020-21: Business Overview
FY 2020-21 : Business Overview Aesthaderm - launched in January 2021: Comprises of “Stunnox” brand (the irst indigenously manufactured botulinum toxin inj in collaboration with Prime Bio - USA) & research based cosmetic formulations such as Moiseta, Revanox and Xtrasun (in collaboration with Lucas M
Slide 4: FY 2020-21: Business Overview
FY 2020-21 : Business Overview API division grew by 40% aided by increased capacities and substantial investments in product development. We aim to launch 5 new molecules in FY 22. The company is in process of applying for IS -6 (one of the molecules for treatment of Black fungus). Expediated approv
Slide 5: Moving in the right direction… to create healthy lives!
Moving in the right direction… to create healthy lives ! Gu ic is a fast-growing research based pharmaceutical company recognized for its innovative, high-quality Pharmaceuticals, Nutraceuticals, Natural/Herbal products. Gu ic is one of the fastest growing company among the top 100 pharma companies
Slide 6: Our broad Business Structure
Our broad Business Structure Domestic Contract Bulk Drug International Business manufacturing Business Business Business 8 well de ined Strategic One of the largest facility Exclusive facility for API. Operation spread across Business Units for Lyophilization Specialization in more than 20 countries
Slide 7: World Class Manufacturing Infrastructure
World Class Manufacturing Infrastructure Gu ic Biosciences Ltd Unit-I Unit-II Gu ic - Vadodara Gu ic - Belgaum Botulinum Toxin facility Lyophilized/powder Lyophilized injectables facility Sanitary Napkins facility Natural products facility injectables facility Natural Products Capability to manufact
Slide 8: Upcoming World Class Manufacturing Infrastructure
Upcoming World Class Manufacturing Infrastructure Gu ic Biosciences Ltd Gu ic Biosciences Ltd Unit-III Unit-IV Lyophilized injectables facility Penem Block Carbapenems Capability to cater regulated (Lyophilized / Dry Powder Inj. markets such as US & EU / Oral Solids ) CAPACITY • Lyophilized – 36 mn
Slide 9: Gufic Biosciences Manufacturing Facility
Gu ic Biosciences Manufacturing Facility Gu ic Biosciences Ltd is a WHO GMP, EU GMP, ANVISA Brazil, Russian GMP, Health Canada, Ukraine GMP, Australia TGA, Colombia INVIMA and Uganda NDA approved company with a total capacity of 30 million lyophilized vials per annum. Product portfolio includes Anti
Slide 10: Botulinum Toxin Facility
Botulinum Toxin Facility Gu ic has built a state - of - the - art manufacturing facility for Botulinum Toxin in Navsari, India. Gu ic has partnered with Prime Bio, USA for manufacturing Botulinum Toxin API and formulation. Gufic is equipped with all the necessary analytical testing procedures for saf
Slide 11: Expanding our Geographical Reach
Expanding our Geographical Reach PRESENCE IN STRATEGIC LOCATIONS ACROSS THE GLOBE Our operations is spread pan- India and 20+ countries worldwide 130+ Products registered globally (in 15+ countries) 150+ products in pipeline for registration (in 30+ countries) • CANADA • COSTA RICA • PANAMA • COLUMB
Slide 12: Consolidating our India Business
Consolidating our India Business India Business Pan - India Presence in multiple Therapy Areas Natural & Ortho-Gynaec Dermo-Cosmetic Critical Care Infertility Mass Specialty Nutraceutical Products Products Products STELLAR Aesthaderm Field Force: > 180 Field Force: > 300 Field Force: > 60 Field Forc
Slide 13: Gufic - Wide-spread Therapy Presence
Gu ic - Wide-spread Therapy Presence Product offerings in Multiple therapy areas across the pharmaceutical market Anti-Infectives Anti Fungal Blood Related Gastrointestinal Women Health Hormones Respiratory Osteoporosis Arthritis Dermo-Cosmetics Pain Wound Care Hepatoprotectives Immunity Infertility
Slide 14: Our strong Partnership and licensing deals
Gu ic - Our strong Partnership and licensing deals Therapy area: Toxins - Strain transfer, Tech-transfer, formulation B o development and manufacturing at Gu ic Therapy area: Infertility Tech-transfer and Clinical development(Phase-III) of the product at Gu ic Therapy area: Dermo-cosmetics Technical
Slide 15: Extensive Sales, Distribution & IT Infrastructure in India
Extensive Sales, Distribution & IT Infrastructure in India 2 Central Warehouses 23 C&F Agents 1200 Plus Stockists 1000 + Field Force Pan India Presence with a field force > 1000+ Two central ware house located in North-Delhi & West-Bhiwandi 23 Carrying & Forwarding agents across India 1200 Stockists
Slide 16: Expanding our credibility in the CMO Business
GUFIC - Expanding Our credibility In the CMO Business Our Esteemed Partners We offer CMO services for India and Global markets: Reliable CMO service for quality products over a decade 70 + Companies 150 + Products across multiple therapy areas One of the Largest supplier of formulations-Doxycycline,
Slide 17: Our robust R&D and Clinical team to augment growth
Our robust R & D and Clinical team to augment growth R&D Clinical Team State-of-the-art R&D Facility Strong Clinical team comprising of located in Navsari, Gujarat Medical with expertise in Regulatory Formulation Development Product Development Technology-Transfer Capabilities to take Synthetic and
Slide 18: Building our API Capabilities
Building our API Capabilities Special facility dedicated to API The categories of API’s manufactured are antifungals, antibacterial, anesthetics and intermediates for antifungals Presence in 25+ countries worldwide 70+ customers Pan India Moving in the right direction... to create API capabilities
Slide 19: Our Strategic Growth Levers
Gu ic - Our Strategic Growth Levers India Business Consolidation of the Critical Care / Infertility business Entry into new therapy areas Dermatology - Aesthaderm Strategic focus on Healthcare division with entry into Ortho-Gynecology products through a new division - Stellar Build a robust pipeline
Slide 20: Financial Highlights – FY 2020-21
Financial Highlights – FY 2020-21 Amt in Lacs Quarterly YTD Particulars Q4 FY 21 Q4 FY 20 Growth YTD FY 21 YTD FY 20 Growth Net Sales 13,093 8,707 50% 48,670 37,884 28% EBITDA 2,440 1,365 79% 8,765 5,791 51% EBIDTA Margin % 19% 16% 18% 15% Pro it Before Tax (PBT) 1,705 629 171% 5711 3013 92% PBT Mar
Slide 21: Financial Highlights – FY 2020-21
Financial Highlights – FY 2020-21 REVENUE EBIDTA NET PROFIT 60,000 EBIDTA EBIDTA Margin % Net Pro it Net Pro it Margin % 5,000 10,000 4,500 4,423 50,000 48,670 9,000 8,765 4,000 8,000 40,000 37,884 3,500 35,417 7,000 30,874 5,668 5,791 3,000 6,000 2,678 30,000 24,927 5,000 2,500 2,269 4,323 4,000 2,
Slide 22: Financial Highlights – FY 2020-21
Financial Highlights – FY 2020-21 ROE % 35.00% ROCE % 30.00% 32.05% 30.00% 25.50% 25.00% 24.48% 25.00% 24.16% 20.00% 17.54% 20.00% 18.21% 15.00% 15.00% 10.00% 10.00% 5.00% 5.00% 0.00% FY 19 FY 20 FY 21 0.00% FY 19 FY 20 FY 21
Slide 23: Corporate Citizenship
Corporate Citizenship COMMUNITY HEALTHCARE, EDUCATION, KNOWLEDGE SOCIAL CARE AND Gu ic’s strong focus on SANITATION AND HYGIENE AND RESEARCH CONCERN promoting and supporting the cause of child education Assist people living in areas Assist underprivileged Generate employment has been recognized by S
Slide 24: Thank You
Thank You For any queries, please contact Mr. Avik Das inance@gu icbio.com Ms. Ami Shah (Company Secretary) mgr_legal@gu icbio.com Tel: +91-22-67261000
Gufic Biosciences — Investor Presentation (June 2021) on 6ix